I. Emerman - Seattle Children's Hospital

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Heterogeneity of CFTR Modulator-Induced Sweat Chloride Concentrations in People with Cystic Fibrosis

E. T. Zemanick,I. Emerman, M. Mccreary,N. Mayer-Hamblett, M. N. Warden,K. Odem-Davis,D. R. Vandevanter,C. L. Ren,J. Young,M. W. Konstan

JOURNAL OF CYSTIC FIBROSISno. 4 (2024): 676-684

引用1浏览0WOS引用

WS15.01 Maternal and Fetal Outcomes in the Era of CFTR Modulators (MAYFLOWERS) Study: Interim Update

J.L. Taylor-Cousar,I. Emerman,K. Odem-Davis,P. Vu, N. Cameron, A. Keller,A. Wilson,R. Jain

Journal of Cystic Fibrosis (2024): S27-S27

引用1浏览0引用

124 Maternal and Fetal Outcomes in the Era of CFTR Modulators (MAYFLOWERS) Study: Interim Results

R. Jain,I. Emerman,K. Odem-Davis, N. Cameron, A. Keller,A. Wilson,M. Putman,A. Magaret,J. Taylor-Cousar

Journal of Cystic Fibrosis (2024): S68

引用0浏览0引用

P084 Willingness of People Treated with Elexacaftor/tezacaftor/ivacaftor (ETI) to Participate in Randomized Clinical Trials of New Modulators and Inhaled Antibiotics

D. VanDevanter, K. Odem-Davis,I. Emerman,J. Young,M. Konstan,E. Zemanick,N. Mayer-Hamblett

Journal of Cystic Fibrosis (2023): S89-S89

引用0浏览0引用

WS02.06 Prospectively Evaluating Maternal and Fetal Outcomes in the Era of CFTR Modulators: MAYFLOWERS Study Interim Results

J.L. Taylor-Cousar,I. Emerman,P. Vu, N. Cameron,A. Keller,A. Wilson,M. Putman,R. Jain

Journal of Cystic Fibrosis (2023): S5-S5

引用0浏览0引用

117 Maternal and Fetal Outcomes in the Era of CFTR Modulators (MAYFLOWERS) Study: Interim Results

R. Jain,I. Emerman,P. Vu, N. Cameron, A. Keller,A. Wilson,M. Putman,J. Taylor-Cousar

Journal of Cystic Fibrosis（2023）

引用0浏览0引用

Willingness of People with Cystic Fibrosis Receiving Elexacaftor/tezacaftor/ivacaftor (ETI) to Participate in Randomized Modulator and Inhaled Antimicrobial Clinical Trials

D.R. VanDevanter,E.T. Zemanick,M.W. Konstan,C.L. Ren,K. Odem-Davis,I. Emerman,J. Young,N. Mayer-Hamblett

Journal of Cystic Fibrosisno. 4 (2023): 652-655

引用1浏览0WOS引用

Willingness of People with Cystic Fibrosis Receiving Elexacaf Tor/tezacaf Tor/ivacaf Tor (ETI) to Participate in Randomized Modulator and Inhaled Antimicrobial Clinical Trials

D. R. Vandevanter,E. T. Zemanick,M. W. Konstan,C. L. Ren,K. Odem-Davis,I. Emerman,J. Young,N. Mayer-Hamblett

JOURNAL OF CYSTIC FIBROSIS（2023）

引用0浏览0引用

43 Cystic Fibrosis Transmembrane Conductance Regulator Modulator–induced Sweat Chloride Changes in the Cystic Fibrosis Population from the Characterizing Cystic Fibrosis Transmembrane Conductance Regulator–Modulated Changes in Sweat Chloride Study: 2022 Update

M. Konstan,N. Mayer-Hamblett,K. Odem-Davis,I. Emerman,D. VanDevanter,C. Ren,J. Young,E. Zemanick

Journal of Cystic Fibrosis (2022): S26-S27

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn